The first clinical trial on DPP-4 inhibitors was published in 2002, and subsequent randomized controlled trials (RCTs) demonstrated their efficacy, safety, and tolerability (15, 17)
J Biol Chem 275:93639368 Mulder H, Lu D, Finley J 4th et al (2001) Overexpression of a modified human malonyl-CoA decarboxylase blocks the glucose-induced increase in malonyl-CoA level but has no impact on insulin secretion in INS-1-derived (832/13) beta-cells
Baca juga : 11 Warna Lipstik untuk Kulit Sawo Matang 1
Because the drug has a ~6-day half-life, missing a single weekly injection by a day or two will not collapse your therapeutic drug levels
GLP-1 plays a crucial role in metabolic syndrome by initiating various health interventions that work in tandem to achieve weight loss and improve health outcomes
Free Radic Biol Med 88(Pt B):290301